The power of monoclonal antibodies (mAbs) recognized by the U.S. Food and Drug Administration
The combined use of monoclonal antibodies (mAbs) was approved by the FDA (U.S. Food and Drug Administration) with encouraging results
The FDA (U.S. Food and Drug Administration) approved, on an emergency basis, the combined use of monoclonal antibodies (mAbs) bamlanivimab and etesevimab to treat medium and low severity cases of Covid-19 in adult and pediatric patients. The decision was published on February 9, 2021.
In clinical studies in the United States, the combined use of antibodies has been shown to significantly reduce hospitalizations and deaths stemming from Covid-19. The encouraging results also served to persuade the FDA to approve the treatment specifically for a high-risk group of patients, those aged 65 and over.
This isn’t the first time the world has proof of mAbs’s revolutionary power.
Recently, an experiment with the use of mAbs to treat Ebola virus infections provided encouraging results. Administering mAb114 reduced the number of deaths from 70% down to 35% in patients infected with Ebola, and today, the disease is no longer considered a lethal one. Similar experiments have been produced with SARS-CoV-2, the virus known as Coronavirus and the cause of Covid-19, and can be tested with other infections.
Monoclonal antibodies are nothing more than proteins made in a laboratory that simulate an immune system’s ability to fight pathogens like viruses. Their creation involves a series of processes such as the isolation of antibodies, various tests, and other procedures that can only be performed in specific laboratories by trained professionals; this specialized type of research comes at a high price.
The use of mAbs is considered a priority for Global Pandemic Shield projects, due to their proven healing strength and ability to generate immune responses to several infections endemic in the world. Support this cause, collaborate with research projects to help intensify the power of mAbs, and heal science in the world.